Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715266 | 1.00 | ALOX5 (0.42) | ALOX5MTORCTSKRIPK1CTSS | |
| SCHEMBL3897727 | 1.00 | ALOX5 (0.42) | ALOX5MTORCTSKRIPK1CTSS | |
| SCHEMBL2953235 | 0.83 | PTGS2 (0.47) | ALOX5CTSKCTSS | |
| SCHEMBL21798473 | 0.82 | MTOR (0.53) | ALOX5MTORCTSKRIPK1CTSS | |
| SCHEMBL30034373 | 0.82 | MTOR (0.53) | ALOX5MTORCTSKRIPK1CTSS | |
| SCHEMBL16914053 | 0.81 | ALOX5 (0.57) | ALOX5MTOR | |
| SCHEMBL6672642 | 0.80 | AKT1 (0.42) | CTSKRIPK1CTSSALDH1A1TSHR | |
| SCHEMBL6613322 | 0.79 | ALOX5 (0.47) | ALOX5MTORCTSKRIPK1CTSS | |
| SCHEMBL118082 | 0.79 | ALOX5 (0.47) | ALOX5MTORCTSKRIPK1CTSS | |
| SCHEMBL17241382 | 0.78 | MAPT (0.38) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735286-B1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| EP-1735286-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-27 | — | — | EP | disclosed |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005095353-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | CNR2, CNR1, GPR18 | ALOX5 303/4885MTOR 542/4885CTSK 2792/4885 |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | ALOX5 303/4885MTOR 542/4885CTSK 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.